A breakthrough in stroke rehabilitation
The Centers for Medicare and Medicaid Services (CMS) has established a latest Health Care Common Procedure Coding System (HCPCS) Level II code for the IpsiHand™ Upper Extremity Rehabilitation System from Neurolutions, Inc. This essential decision marks the primary use of a brain-computer interface. Controlled therapy (BCI) has been recognized by receiving the HCPCS code, setting a latest benchmark for thought-activated devices.
E0738 can be used to explain “Upper limb rehabilitation system providing energetic assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to explain the IpsiHand upper limb rehabilitation system.
The IpsiHand system is a breakthrough therapeutic device and the one FDA-approved solution available available on the market that allows non-invasive rehabilitation at home for stroke survivors affected by chronic motor deficits. Using BCI technology, IpsiHand provides stroke survivors with thought-activated therapy that mixes movement with intention to maneuver signals within the brain, thereby helping to rebuild neural pathways.
The CMS decision also includes the ultimate determination of the Medicare profit category, classifying IpsiHand as durable medical equipment (DME). This classification highlights IpsiHand’s durability and suitability for home use, further emphasizing its role in improving patient care and recovery outcomes. Neurolutions CEO Leo Petrossian expressed enthusiasm about CMS’ decision, stating:
“We thank CMS for its decision and commitment to enhance outcomes for stroke survivors by establishing the brand new HCPCS code, and for its support throughout the appliance process. This essential milestone is a testament to Neurolutions’ revolutionary spirit and significant shift toward improving access to advanced rehabilitation technologies for stroke survivors across the country.”
This can be a step forward towards the coverage of upper extremity rehabilitation therapy, opening the door to advances in therapeutic BCI to attain higher outcomes for patients and potentially reduce the price of care. Neurolutions is proud to partner with CMS to advance leadership within the rapidly evolving field of BCI-based stroke neurorehabilitation.
About Neurolutions, Inc.
Neurolutions is a medical technology company committed to changing the lives of patients affected by neurological conditions. Our mission is to develop revolutionary solutions to deal with unmet patient needs while advancing the sphere of neurorehabilitation through cutting-edge research and development.
The IpsiHand system is a breakthrough therapeutic device that uses brain-computer interface technology to assist chronic stroke patients with upper limb impairment regain the power to maneuver. The IpsiHand device is clinically approved and has received FDA approval to be used in the USA.